415 CAPITAL

415 Capital is a Munich-based venture capital firm that specializes in investing in breakthrough medical technologies, particularly those addressing critical unmet needs in cardiovascular and neurovascular diseases. With a focus on improving patient outcomes and reducing healthcare costs, 415 Capital invests in startups across Europe, Israel, and North America, typically writing checks between €5 million and €15 million per company. The firm’s portfolio boasts several cutting-edge companies like Supira Medical, which is developing a percutaneous ventricular assist device for high-risk heart patients, and Distalmotion, known for its innovative surgical robotics platform. 415 Capital avoids biotech, healthcare services, and wellness products, honing in exclusively on medtech innovations. Their strategy emphasizes deep involvement from the R&D stage through commercialization, leveraging close relationships with healthcare providers and access to a €2 billion commercial channel in Europe. The firm’s team combines expertise in investment, medical device commercialization, and clinical practice, ensuring they remain at the forefront of medical innovation. Historically, 415 Capital has been part of significant advancements such as the development of transcatheter heart valves and renal denervation technologies. Their approach to venture capital is deeply rooted in the belief that pioneering medical technologies can simultaneously improve healthcare and generate substantial returns.